We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 06, 2022

Switching to 6-Week Dosing of Natalizumab vs Continuing With 4-Week Dosing in Patients With Relapsing–Remitting MS

The Lancet Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Lancet Neurol 2022 Apr 25;[EPub Ahead of Print], JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, G Cutter, G Giovannoni, J Killestein, H Wiendl, K Smirnakis, S Xiao, G Kong, R Kuhelj, N Campbell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading